ERBB2 and breast carcinoma: Numerous studies have implicated Rac/PAK activities with the maintenance of mesenchymal stem cell-like populations in epithelial cancers; and thus, therapy resistance, especially in HER2-type breast cancer [33, 36, 38–43, 79–86].